Jul 12, 2021
As physicians and health policy experts debate the merits of Aduhelm, the first new drug for Alzheimer’s disease approved in 18 years, patients want to know: “Will this medication help me and how much?”
Doctors explaining the pros and cons of Aduhelm won’t have a definitive answer. “On an individual basis, it will be absolutely impossible to predict,” said Dr. Allan Levey, director of the Goizueta Alzheimer’s Disease Research Center at Emory University.
Cognitive decline varies widely among people who have started experiencing memory and thinking problems or who are in the earliest stage of Alzheimer’s the patients in whom Aduhelm was tested, Levey noted.
New-york
United-states
Mount-school
Michigan
Northwell
Nevada
Las-vegas
Henry-paulson
Judith-graham
Samuel-gandy
Allan-levey
Aaron-ritter